Elicio Therapeutics (ELTX) - Scientific Deep Dive for ELI-002 7P and the AMP Pipeline

Executive Summary

The Hook. Elicio is trying to do what no one has done in a randomized trial: turn an off-the-shelf, lymph-node-targeted peptide vaccine against shared mutant-KRAS driver mutations into a recurrence-prevention drug for resected pancreatic cancer — the deadliest common solid tumor.

The Bull Case. ELI-002 7P is off-the-shelf (no per-patient manufacturing), monotherapy (no checkpoint inhibitor or chemo backbone required), cheap to make, and clean on safety. It targets seven mKRAS variants present in ~25% of solid tumors. The Phase 1 single-arm data are eye-catching: full-cohort median overall survival (OS) of 28.94 months versus a ~17-month historic benchmark in the same minimal-residual-disease (MRD+) PDAC setting, with an 88% reduction in relapse/death risk among above-threshold T cell responders. If the randomized Phase 2 AMPLIFY-7P disease-free survival (DFS) readout — expected by mid-2026 — confirms a benefit, Elicio becomes the first validated KRAS-directed vaccine in adjuvant PDAC, a multi-billion-dollar setting, and a logical combination partner for the RAS-inhibitor wave. At a ~$250M market cap, that re-rate is a multibagger.

The Bear Case. Every data point Elicio has released from the randomized Phase 2 is immunogenicity (T cells go up); the company “remains blinded to the trial efficacy outcomes”. The entire thesis rests on the unproven leap that T cell responses translate into randomized DFS benefit — the exact leap that has killed a generation of cancer vaccines. The impressive survival figures are single-arm, n=25, in a hand-picked MRD+ population compared to historic controls. Meanwhile the balance sheet is on life support: substantial-doubt going-concern language, negative stockholders’ equity, a continuous at-the-market (ATM) dilution drip, and a 12.5% secured note from a board member’s entity that sits ahead of equity holders. And the competitive setting just got far more dangerous: Revolution Medicines’ oral pan-RAS inhibitor daraxonrasib posted a positive Phase 3 in metastatic PDAC and is running a Phase 3 in the identical adjuvant-PDAC DFS setting Elicio is targeting. A binary miss on an open-label, investigator-assessed endpoint in a company that can’t fund itself is a path to near-zero.

Bottom Line. This is a genuinely differentiated science wrapped around an unproven efficacy assumption, a broken balance sheet, and a newly validated competitor.

Catalyst Calendar & Financial Runway

Upcoming catalysts (next 12–18 months).

• AMPLIFY-7P Phase 2 final DFS analysis (ELI-002 7P, adjuvant PDAC, NCT05726864) — expected 1H 2026. This is the binary. The trial is a 2:1 randomized study (ELI-002 7P vs. SOC observation), MRD-agnostic, ~144 patients, 24 U.S. sites, primary endpoint investigator-assessed DFS by modified RECIST. An event-driven interim was completed Q3 2025 with management characterizing “preliminary signals of efficacy” and IDMC-confirmed safety; on the FY2025 call, management noted “fewer disease progressions and deaths to date than projected”. Note: “1H 2026” means the readout is essentially now.

• End-of-Phase-2 FDA meeting — to be requested after the final DFS analysis.

• Phase 3 adjuvant-PDAC protocol — to be finalized; design reportedly aligned in a prior Type B meeting.

• Investigator-sponsored combinations (subject to funding): ELI-002 7P + checkpoint inhibitor in neoadjuvant PDAC (Memorial Sloan Kettering, Lustgarten-funded) and metastatic MSS CRC; ELI-004 + radiation in sarcoma.

• Pipeline-readiness milestones (subject to funding): ELI-007 (BRAF) and ELI-008 (p53) toward Phase 1; next-generation AMP-DNA adjuvant published in Science Advances June 2026.

Note the recurring phrase “subject to funding.” It appears on nearly every non-lead program in the deck — an honest tell that the pipeline beyond ELI-002 7P is aspirational until the balance sheet is fixed.

The Dilution Gap.

• Cash and equivalents were $18.6M at December 31, 2025 and $14.9M at March 31, 2026.

• Q1 2026 operating cash outflow was ~$11.6M (net loss $11.8M; operating expenses $10.6M, split $6.8M R&D / $3.8M G&A) — a burn of roughly $3.9M per month.

• The accumulated deficit is $245.5M and stockholders’ equity is negative (-$1.4M).

• Management discloses substantial doubt about the company’s ability to continue as a going concern, with runway “into the fourth quarter of 2026” — and only with continued ATM sales.

Here is the dilution math that matters: the runway extends just past the 1H 2026 DFS readout, but the company is funding itself hand-to-mouth. It raised ~$8.0M net via ATM in Q1 2026 and another ~$5.0M through May 8, 2026. The ATM is always on — so a raise isn’t “likely before the next data drop,” it is continuous and ongoing.

On top of equity, Elicio carries a $10.0M Senior Secured Promissory Note from GKCC, LLC — an entity controlled by a member of its own board — bearing interest of up to 12.5% and secured by substantially all company assets, due June 3, 2028. That is a lifeline, not a vote of equity confidence: in a downside scenario the board-affiliated secured creditor is first in line, ahead of common holders.

Unambiguous read: a dilutive raise is structurally certain. Good DFS data → a larger marketed offering at a higher price (manageable). A miss → the equity is impaired and the secured note holder controls the assets.

Insiders & Institutions. Individual insiders hold roughly 36% of the company, and as of early 2026 ELTX was characterized as not owned by hedge funds. The legacy holders are Access Industries and Clal Biotechnology Industries — strategic/legacy investors carried over from the Angion reverse merger, not specialist biotech crossover funds. Critically, none of the specialist oncology anchor funds — RA Capital, Baker Bros, Fairmount, Perceptive, Deep Track, Avoro, or EcoR1 — appear in the ownership filings. For a company claiming randomized “signals of efficacy” in adjuvant PDAC, that absence is a signal in itself: the crossover capital that floods de-risked oncology names with real data has not shown up. The only fresh “smart money” is a board member writing a 12.5% secured loan.

The Science: Mechanism & Chemistry

ELI-002 is a synthetic-peptide therapeutic cancer vaccine built on the Amphiphile (“AMP”) platform — a lymph-node delivery chemistry, not a new molecular entity in the small-molecule sense. It pairs AMP-modified mutant-KRAS peptide antigens with ELI-004, an AMP-modified CpG oligonucleotide (a TLR-9 agonist adjuvant). Modality novelty is “first-in-class delivery” rather than first-in-class target.

Mechanism validation. The target — mutant KRAS — is among the most validated oncology targets in existence, de-risked by approved small molecules (Amgen’s Lumakras/sotorasib and Bristol Myers Squibb’s Krazati/adagrasib) and by the daraxonrasib Phase 3 discussed in Section 5. What is not yet validated is the modality: no KRAS-directed or neoantigen vaccine has shown a randomized efficacy benefit in adjuvant PDAC. So Elicio is “validated target, unvalidated approach.”

Manufacturing / CMC. This is a genuine advantage. As a synthetic, off-the-shelf, subcutaneously administered vaccine, ELI-002 sidesteps the autologous-cell logistics and weeks-long personalized manufacturing that burden competitors like autogene cevumeran. Low cost of goods and rapid availability are real differentiators, particularly for neoadjuvant and prophylactic settings.

Biochemical Deep Dive

The Target. KRAS is a small GTPase that cycles between GDP- (off) and GTP-bound (on) states to drive MAPK proliferative signaling. Oncogenic mutations at codons G12, G13, and Q61 lock KRAS “on.” mKRAS is truncal (present early, uniformly expressed) and a public neoantigen (shared across patients, not centrally tolerized) — which is precisely what makes an off-the-shelf, shared-antigen vaccine conceptually possible. In PDAC, ~88% of tumors carry a KRAS mutation, so antigen coverage is broad.

The Chemistry. The AMP trick is albumin hitchhiking. Each construct is a three-part conjugate: a diacyl (albumin-binding) lipid tail, a PEG polymeric linker, and a payload (either an mKRAS peptide or the CpG adjuvant). On subcutaneous injection, the lipid latches onto endogenous tissue albumin (~65 kDa), and albumin’s natural trafficking ferries the payload into draining lymph nodes — where antigen presentation and T cell priming actually occur — rather than letting it diffuse into the bloodstream. The differentiating receipt: in preclinical work, AMP-modification drove a >22-fold increase in antigen-specific IFN-γ+ CD8 T cells versus soluble peptide (52% vs. 2% of CD8 T cells in the cited model). The 7P formulation extends antigen coverage to G12D/R/V/C/A/S and G13D.

The Mechanism. AMP-CpG (ELI-004) engages TLR-9 to activate antigen-presenting cells and create a pro-inflammatory lymph-node environment; AMP-peptides supply the mKRAS antigen. The result is de novo priming and expansion of polyfunctional CD4+ and CD8+ mKRAS-specific T cells, plus antigen spreading — induction of T cells against personalized tumor neoantigens not contained in the vaccine, observed in 87% of tested Phase 2 patients. The newer AMP-DNA adjuvant adds a distinct TBK1/type-I-interferon innate axis.

The Biomarker Receipts. T cell responses are detectable by direct ex vivo FluoroSpot/flow cytometry without expansion — a meaningful quality signal. In the randomized Phase 2 (n=90 evaluable, 4.9 mg), 99% of patients mounted mKRAS-specific T cell responses, with a 44.3x median fold-change over baseline and 85% inducing both CD4 and CD8 responses, robust across 1,132 unique HLA types. The pharmacodynamics are unambiguous: the vaccine reliably makes the intended T cells.

Bottom line for the thesis. The biology is real and the mechanism is demonstrably engaged in patients. But pharmacodynamics is the easy part of an immunotherapy. The question is whether these T cells reduce relapse in a randomized comparison — and the Company does not yet answer it, because they are blinded to efficacy.

Clinical Data

Efficacy — what exists, and what doesn’t. The headline numbers are from the single-arm Phase 1 AMPLIFY-201 (ELI-002 2P, n=25 MRD+ PDAC/CRC): full-cohort median RFS 16.33 months and median OS 28.94 months at the September 2024 cutoff. Against the company’s cited historic MRD+ PDAC benchmark (RFS ~5–6.4 months, OS ~17 months), that looks transformative.

Cross-trial caveat — read this twice. Those comparisons are cross-trial, single-arm, n=25, and population-selected. Two specific traps:

• Denominator/population shift. The Phase 1 survival figures are in MRD+ (ctDNA-positive) patients — a worst-prognosis subset. The randomized Phase 2, by contrast, is MRD-agnostic (biomarker +/- included). That raises the control-arm bar: an all-comers resected-PDAC population that has completed adjuvant chemo has a much longer expected DFS than the 5–6-month MRD+ figure. For context, adjuvant modified FOLFIRINOX delivers a median DFS of ~21.6 months in all-comers resected PDAC (versus 12.8 months with gemcitabine; HR 0.58), and the no-treatment observation arm in CONKO-001 ran ~6.7 months. The point: the impressive Phase 1 deltas were measured against the hardest benchmark; the randomized Phase 2 is a cleaner, harder test.

• Biomarker-stratified framing. The “88% reduction in risk of relapse or death” (HR 0.12, P=0.0002) and “77% reduction in risk of death” (HR 0.23, P=0.0099) compare above-threshold T cell responders to below-threshold patients within the same uncontrolled trial. The 9.17x threshold was ROC-defined (data-derived). Responders-vs-non-responders within a single arm is suggestive of a mechanism link, but it is not a randomized treatment effect, and it is vulnerable to selection (patients healthy enough to mount immune responses tend to have better outcomes regardless of cause). Do not read these hazard ratios as the expected randomized effect size.

The P-Hacking check. Beyond the above-threshold framing, note the design risk: AMPLIFY-7P is described in the same deck slide as both a “2:1 Randomized, Open Label Study” and a “Randomized, blinded trial” with “investigator-assessed DFS”. An open-label trial with an investigator-assessed primary endpoint invites assessment bias — partially, but not fully, mitigated by the protocol’s requirement that new lesions be confirmed by biopsy/imaging. The mitigant that the company “remains blinded to efficacy outcomes” applies to the sponsor’s analysis, not to open-label treating investigators. Weigh the eventual DFS hazard ratio against this.

Safety / Tolerability — the quiet killers (here, mostly absent). This is the cleanest part of the story. Across the Phase 1 trials, no dose-limiting toxicities, no cytokine release syndrome, no treatment-related SAEs; the most common treatment-related adverse events were Grade 1 fatigue (~43%) and malaise (~21%). For an adjuvant (recurrence-prevention) drug given to otherwise disease-free patients, a benign safety profile is exactly what you want and is a real competitive edge versus chronic oral inhibitors with rash/stomatitis or chemo backbones.

Data integrity. Phase 1 was open-label, single-arm, dose-ranging (2P n=25; 7P n=14). The Phase 2 is randomized 2:1 vs. observation, open-label, ~144 patients across 24 U.S. sites, primary endpoint investigator-assessed DFS. The randomized DFS analysis — not yet released — is the first methodologically sound efficacy test in the program’s history.

Pipeline

ELI-002 7P (mKRAS; PDAC adjuvant — lead). Randomized Phase 2 DFS readout imminent (1H 2026). This single asset carries essentially the entire valuation. Value driver.

ELI-002 7P (mKRAS; CRC and metastatic/neoadjuvant settings). Phase 1 basket signal plus planned investigator-sponsored combinations with checkpoint inhibitors. Optionality contingent on the PDAC readout and outside funding.

ELI-004 + radiation (sarcoma); AMP-DNA adjuvant. ELI-004 is the AMP-CpG adjuvant repurposed as an intratumoral immune activator; AMP-DNA is a next-gen adjuvant (TBK1/IFN-I) with fresh Science Advances preclinical data. Platform-credibility assets, near-zero current NPV.

ELI-007 (BRAF) and ELI-008 (p53). Preclinical/IND-readiness AMP vaccines against mutant BRAF (~95% of BRAF mutants via V600E/K) and p53 hotspots (~1/3 of p53 mutants via 12 variants). Strong preclinical T cell data (>19x for BRAF, >300x for p53 hotspots in mice), but mouse immunogenicity is cheap. Optionality only.

PRV note. No Rare Pediatric Disease Designation is in play here, so no Priority Review Voucher value to fold into a sum-of-the-parts.

Pipeline Verdict. This is a one-asset story. ELI-002 7P in adjuvant PDAC carries the valuation; everything else is platform optionality that only becomes investable if the lead succeeds and the company secures non-dilutive or strategic capital.

Intellectual Property & The Moat

The summary provided below is based on the Form 10-K filed by the Company in March 2026 and the Form 10-Q filed in May 2026.

The core AMP platform is in-licensed from MIT, not owned. The company reports that the MIT-licensed patent rights cover its lead programs in tumor indications where mutant KRAS, mutant BRAF, or mutant TP53 are drivers, plus programs using CpG as an adjuvant. The company further reports that its ability to develop and commercialize ELI-002 is “substantially dependent on the legal effectiveness of the MIT patent rights licensed under this agreement and continuation of this agreement,” and that MIT controls the preparation, filing, prosecution, maintenance, and defense of those patents.

The moat reality. This is the central IP weakness. A licensed-platform structure means: (a) the company does not own its foundational composition-of-matter estate; (b) MIT — not Elicio — drives prosecution and enforcement strategy; (c) the relationship carries the usual royalty/milestone obligations and change-of-control exposure typical of academic licenses; and (d) the company explicitly flags that the license is “complex” and “susceptible to multiple interpretations.” The filings reviewed do not lay out specific composition-of-matter expiration windows for the AMP/ELI-002 estate — itself a notable absence for an asset this central. Treat all patent characterizations as company-reported and unverified against the docket.

Competitive landscape — the shark tank. This is where the thesis took on water in 2026.

• Daraxonrasib (RMC-6236, Revolution Medicines) — the new apex predator. This oral, multi-selective RAS(ON) inhibitor reported a positive Phase 3 (RASolute 302) in previously treated metastatic PDAC, roughly doubling median OS versus chemotherapy — 13.2 months vs. 6.7 months (HR 0.40; P<0.0001) in the ITT population — with regulatory filings underway. Critically for Elicio, Revolution Medicines is also running RASolute 304, a Phase 3 of adjuvant daraxonrasib versus SOC observation in resected PDAC with a DFS primary endpoint in patients who have completed neoadjuvant and/or adjuvant chemotherapy. That is the same setting, same endpoint, same comparator as AMPLIFY-7P — run by a far better-capitalized company with a validated, mechanistically direct modality. A once-daily pill that already doubles survival in metastatic disease is a more de-risked adjuvant bet than an immunogenicity-only vaccine.

• Autogene cevumeran (BNT122, BioNTech/Genentech). A personalized mRNA neoantigen vaccine in adjuvant PDAC; Phase 1 showed T cell responders with delayed recurrence, and a randomized Phase 2 is ongoing but has not read out efficacy. It requires a checkpoint-inhibitor + chemo backbone and ~9-week personalized manufacturing — which is precisely the complexity Elicio’s off-the-shelf approach undercuts. Notably, neither program has randomized efficacy yet, so Elicio’s AMPLIFY-7P could be the first randomized adjuvant-PDAC readout in the vaccine class — first-mover upside, but also unprecedented-modality risk.

• KRAS G12C inhibitors (Lumakras/sotorasib, Krazati/adagrasib). Validate the target but are G12C-only and limited-duration; not direct adjuvant-PDAC competitors.

The differentiation Elicio claims (off-the-shelf, monotherapy, clean safety, broad mKRAS coverage) is real. But “differentiated” is not “better” until a randomized endpoint says so — and a pan-RAS pill in the same adjuvant trial is a structural threat to the entire commercial thesis.

The Verdict

• Scientific Conviction: Medium. The lymph-node-targeting chemistry is legitimate and the pharmacodynamics are elite; the unproven link from T cell response to randomized DFS keeps this out of “High.”

• Commercial Viability: Low-to-Medium. Off-the-shelf economics are attractive, but a validated oral pan-RAS competitor in the same adjuvant trial caps pricing power and standalone positioning.

• M&A Appeal: Low (pre-data) / Medium (post-positive-data). Logical acquirers are the RAS/IO players — Amgen, BMS, Merck, Roche/Genentech, or Revolution Medicines as a combo partner. But the licensed-from-MIT IP, going-concern balance sheet, and unproven modality mean no acquirer pays up before randomized DFS. A clean positive readout could change that quickly given the off-the-shelf combo logic.

• Trader Profile. Binary-event gamblers only. This does not appear to be a compounder, nor an M&A specvestor’s safe setup, and nor a name to hold blindly through the readout. The stock has already run ~170% over the past year and ~30% in the past week into the catalyst — classic catalyst-anticipation accumulation, now near 52-week highs (~$12–14, ~$250M market cap).

BUY thesis.

• Target audience: High-risk-tolerant binary speculators who want first-mover exposure to a potential first-ever randomized win for a KRAS vaccine in adjuvant PDAC.

• Rationale: Clean safety, off-the-shelf economics, 99% immunogenicity, management’s “fewer events than projected” interim commentary, and a sub-$250M cap that re-rates hard on a positive HR.

• Execution/strategy: Size as a lottery ticket — money you can lose entirely. Because runway extends just past the readout, the stock can move on data before a raise. If options exist and are liquid, defined-risk long calls or call spreads are the sane way to express upside without naked downside. Trim/exit into any “buy-the-rumor” run rather than holding the full position naked through the binary.

HOLD thesis.

• Target audience: Existing holders sitting on the catalyst run-up.

• Rationale: The interim color is encouraging and the readout is close, but the risk/reward is now two-sided with the stock near highs.

• Execution/strategy: Apply trim-pre-binary discipline — take enough off to recover cost basis and let a house-money stub ride the readout. Think twice before adding into the spike.

SELL / AVOID thesis.

• Target audience: Investors who require randomized efficacy, a funded balance sheet, or specialist-fund validation before committing.

• Rationale: No randomized efficacy yet; going concern with negative equity and a 12.5% secured insider note; continuous ATM dilution; a newly validated pan-RAS competitor in the same adjuvant setting; licensed-not-owned core IP; and a conspicuous absence of biotech crossover capital.

• Execution/strategy: Stand aside until the DFS data and the inevitable post-data financing are on the table. There is no penalty for buying a confirmed randomized win the day after; there is a large penalty for owning the miss.

Final Verdict

WATCH LIST. The science is differentiated and the binary is imminent, but with zero randomized efficacy data, a going-concern balance sheet, and a freshly validated pan-RAS competitor entering the same adjuvant trial, this is a speculation to size as a lottery ticket — not a position to underwrite — until the AMPLIFY-7P DFS data clears the bar.

This report is strictly for informational and educational purposes only. It does not constitute financial advice, investment advice, or a recommendation to buy or sell any securities mentioned.

The scientific and clinical analyses herein should not be interpreted as medical guidance, diagnostic information, or treatment recommendations.

At the time of writing, the author does not hold a position in Elicio Therapeutics (ELTX).

Biotech investing is inherently volatile. Past scientific validation does not guarantee future clinical or regulatory success. Treat all clinical-stage biopharma allocations accordingly.